|
|
|
|
These data confirm that intravenous alteplase is safe and effective in routine clinical use when used within 3 h of stroke onset, even by centers with little previous experience of thrombolytic therapy for acute stroke. The findings should encourage wider use of thrombolytic therapy for suitable patients treated in stroke centres. |
|